Gabather
1.98 SEK +7.61%1 investor is following this company
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GABA
Daily low / high price
1.845 / 2.05
SEK
Market cap
37.39M SEK
Turnover
82.58K SEK
Volume
42K
Financial calendar
Interim report
2024-05-30
General meeting
2024-06-30
Interim report
2024-08-29
Interim report
2024-11-28
Annual report
2025-02-27
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 14.5 % | 14.5 % |
Nordnet Pension | 2.6 % | 2.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002
Gabather AB: Teckningskursen för utyttjande av teckningsoptioner av serie TO5 i Gabather har fastställts till 1,30 SEK per aktie inför teckningsperioden som inleds den 11 april 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools